L

LAURIA R.

Last name: LAURIA R.

2021 (v1)

Publication

Metadata-only

Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': (ESMO Open (2021) 6(2), (S2059702921000089), (10.1016/j.esmoop.2021.100054))

De Angelis C. Bruzzese D. Bernardo A.

The authors regret that at the time the article was published the following two authors were missing from the author list: R. Caputo and D. Cianniello. Both authors affiliation is the Breast Oncology Department, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy. The updated author list is as follows: C. De Angelis, D. Bruzzese, A....

Uploaded on: February 14, 2024
2020 (v1)

Publication

Metadata-only

Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: Extending endocrine sensitivity

Frassoldati A. Biganzoli L. Bordonaro R.

Targeted agents have significantly prolonged survival and improved response rates in first- and second-line settings of hormone receptor-positive/HER2-negative metastatic breast cancer. Optimal sequencing of the available options may prolong endocrine sensitivity, slow disease progression and delay the need for chemotherapy. However, the...

Uploaded on: April 14, 2023